Texas City

Researchers are evaluating a new combination of medicines, DSP107 and atezolizumab, compared with an existing treatment, fruquintinib, for patients with advanced microsatellite stable colorectal cancer. This Phase 2b, randomized, open-label study focuses on individuals whose cancer has progressed or who cannot tolerate standard therapies. The study aims to assess whether the new combination improves treatment outcomes and safety compared to the current treatment options. Participants are randomly assigned to one of two groups. One group receives DSP107 intravenously on Days 1, 8, and 15 of each 28-day cycle with atezolizumab given intravenously on Day 1. The other group takes fruquintinib orally once daily on Days 1 to 21 of each 28-day cycle. The study includes a screening period of up to 28 days, a treatment period lasting up to 24 cycles, a safety follow-up period of up to 90 days after the last dose, and a long-term follow-up lasting up to 5 years from randomization. During the study, participants will have medical evaluations including monitoring of cancer response, safety assessments, and tests such as ECG and blood pressure measurements. Quality of life and immune response to treatment will also be tracked. Participants maintain dosing diaries if assigned to the oral treatment group. The primary outcome is overall survival, with ongoing safety and health status follow-up conducted for several years after treatment. Total study participation duration varies based on treatment tolerability and disease progression.

Researchers are observing the safety and performance of Terumo Aortic endovascular grafts used to treat patients with aortic aneurysms and other related conditions during routine clinical practice. This global, multi-center registry collects real-world data to better understand outcomes after these devices have been approved and are in use. The study is open label and includes multiple groups based on the type of aneurysm or device implanted. Participants receive one of several types of Terumo Aortic endovascular stent-grafts, including Thoracic Relay stent grafts, Abdominal Anaconda or Treo grafts, custom fenestrated devices, and Iliac artery-specific implants. These devices are CE marked or custom-made and are implanted following standard clinical procedures. The registry tracks patients treated with these devices in usual care settings without altering treatment. During the study, participants will attend follow-up visits where researchers collect safety data, patient-reported outcomes, and health economic information. Key outcomes measured include aortic-related mortality within 30 days post-implant, technical success on the day of surgery, and composite clinical success and additional endpoints at one year. The registry aims to monitor long-term performance and safety of these grafts in real-world use, with participation lasting as determined by follow-up schedules.